Key points are not available for this paper at this time.
It is not clear a patient treated for neurodegenerative condition prone to increased risk for some types of cancer and vice versa. This is necessary to keep in mind during rational drug design process for all therapies, which are based on AChE as a target molecule.
Lazarević‐Pašti et al. (Wed,) studied this question.